ARTICLE | Company News
UCLA, Bone Biologics deal
June 27, 2016 7:00 AM UTC
UCLA granted Bone Biologics an option to license exclusive, worldwide rights to use NEL-like protein 1 (NELL1) to treat osteoporosis. Bone Biologics is funding development of a NELL1-based product to...